Matrix metalloproteinase-9, its inhibitor-1 and interleukines in experimental traumatic brain injury

Authors

  • S. V. Ziablitsev Bogomolets National Medical University,
  • Ya. S. Yuzkiv Bogomolets National Medical University,

DOI:

https://doi.org/10.14739/2310-1237.2016.3.86944

Keywords:

traumatic brain injury, matrix metalloproteinase-9, matrix metalloproteinase inhibitor-1, interleukines

Abstract

Traumatic brain injury (TBI) is accompanied by high rates of morbidity and mortality in both developed and undeveloped countries that makes it one of the most actual medical and social problems. In recent years matrix metalloproteinases are in increasing interest while studying TBI pathogenesis because of their ability to increase permeability of the blood-brain barrier and to cause nervous tissue matrix reorganization.

The goal of given study was to investigate the role of matrix metalloproteinase MMP-9 and its inhibitor TIMP-1 in pathogenesis of TBI.

Methods: The study was performed on 98 mature white rats. Moderate severity TBI was modeled with one blow on the cranial vault by means of free-falling plummet. Control group included 30 rats. Cytokines (IL-1b, IL-6, IL-8, TNF-a), MMP-9 and TIMP-1 levels were investigated in animals blood by means of ELISA on the 1st, 3rd, 7th, 14th and 21st days after trauma.

Results and discussion: MMP-9 levels increased by only 38,2% on the 1st day, but on the 3rd day there was its marked increase to 538%. It is known that metalloproteinases are released from the cells under the influence of various factors, including cytokines. On the 1st day after trauma it was IL-1β which increased by 705% showing the highest rise among other cytokines and exceeding increase in MMP-9 levels. This might indicate regulatory role of IL-1β. A marked increase in MMP-9 levels in its turn led to TIMP-1 activation. Significant increase in TIMP-1 levels was determined on the 3rd day after trauma. On the 7th day there was a critical period with the highest levels of IL-1β (2147,2%), MMP-9 (720,3%) and TIMR-1 (339,3%). Then all research indicators were decreasing with the most pronounced decrease in IL-1β and MMP-9.

Conclusion: MMP-9 levels began to increase on the 1st day after trauma due to influence of mainly IL-1β. An abrupt increase in MMP-9 in its turn caused an increase in TIMR-1 levels. Identified changes in IL-1β, ММР-9 and ТІМР-1 levels after TBI indicate complex relationships between cytokines and intercellular matrix reorganization regulators in formation of intercellular cooperation and neuroinflammation development.

 

 

References

El´skij, V. N., & Zyablicev, S. V. (2008). Modelirovanie cherepno-mozgovoj travmy [Design of brain injury]. Donetsk: New world. [in Ukrainian].

Ziablitsev, S. V., Yuzkiv, Ya. S., & Dyadyk, O. O (2016). Dynamika vmistu neirospetsyfichnykh bilkiv ta yikh utvorennia pry eksperymentalnii cherepno-mozkovii travmi [Dynamics of neurospecifi c proteins content and their formation in experimental brain injury]. Pathologia, 1(36), 49–53. [in Ukrainian]. doi: 10.14739/2310-1237.2016.1.71574.

Pobedyonniy A.L. (2011). Rasprostranennost' i struktura cherepno-mozgovoj travmy v krupnom promyshlennom regione [Prevalence and structure of cranio-cerebral trauma in large industrial region]. Ukrainskyi neirokhirurhichnyi zhurnal, 3, 32–35. [in Ukrainian].

Rogova, L. N., Shesternina, N. V., Zamechnik, T. V., & Fastova, I. A. (2011). Matriksnye metalloproteinazy, ikh rol' v fiziologicheskikh i patologicheskikh processakh (obzor) [Matrix metalloproteinases, their role in physiological and pathological processes (review)]. Vestnik novykh medicinskikh tekhnologij, ХVIII(2), 86–89. [in Russian].

Alluri, H., Wilson, L., Anasooya S. C., Wiggins-Dohlvik, K., Patel, S., Liu, Y., et al (2016). Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One, 11(5), e0154427. doi: 10.1371/journal.pone.0154427.

Bender, A., Adrion, C., Fischer, L., Huber, M., Jawny, K., Straube, A., & Mansmann, U. (2016). Long-term rehabilitation in patients with acquired brain injury. Dtsch. Arztebl. Int., 113(38), 634–641. doi: 10.3238/arztebl.2016.0634.

Bener, A., Omar, A. O., Ahmad, A. E., Al-Mulla, F. H., & Abdul Rahman, Y. S. (2010). The pattern of traumatic brain injuries: a country undergoing rapid development. Brain Inj., 24(2), 74–80. doi: 10.3109/02699050903508192.

Cnossen, M. C., Polinder, S., Lingsma, H. F., Maas, A. I., Menon, D., & Steyerberg, E. W. (2016). Variation in structure and process of care in traumatic brain injury: provider profiles of european neurotrauma centers participating in the CENTER-TBI Study. PLoS One, 11(8), e0161367. doi: 10.1371/journal.pone.0161367.

Guilfoyle, M. R., Carpenter, K. L., Helmy A., Pickard, J. D., Menon, D. K., & Hutchinson, P. J. (2015). Matrix metalloproteinase expression in contusional traumatic brain injury: A Paired Microdialysis Study. J. Neurotrauma, 32(20), 1553–1559. doi: 10.1089/neu.2014.3764.

Hsu, J. Y., Bourguignon, L. Y., Adams, C. M., Peyrollier, K., Zhang, H., Fandel, T., et al. (2008). Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J. Neurosci., 28(50), 13467–13477. doi: 10.1523/JNEUROSCI.2287-08.2008.

Peeters, W., van den Brande, R., Polinder, S., Brazinova, A., Steyerberg, E. W., Lingsma, H. F., & Maas, A. I. (2015). Epidemiology of traumatic brain injury in Europe. Acta Neurochir., 157(10), 1683–1696. doi: 10.1007/s00701-015-2512-7.

Zhang, H., Adwanikar, H., Werb, Z., & Noble-Haeusslein, L. J. (2010). Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist., 16, 156–170. doi: 10.1177/1073858409355830.

Downloads

How to Cite

1.
Ziablitsev SV, Yuzkiv YS. Matrix metalloproteinase-9, its inhibitor-1 and interleukines in experimental traumatic brain injury. Pathologia [Internet]. 2016Dec.23 [cited 2024Apr.26];(3). Available from: http://pat.zsmu.edu.ua/article/view/86944

Issue

No. 3 (2016)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).